We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+19.33%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.67B
AUM Growth
+$125M
Cap. Flow
+$47M
Cap. Flow %
1.76%
Top 10 Hldgs %
52.29%
Holding
77
New
9
Increased
18
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$132M
2
ARGX icon
argenx
ARGX
+$78.1M
3
IMA
ImageneBio Inc
IMA
+$45.7M
4
CGEM icon
Cullinan Oncology
CGEM
+$42.6M
5
MRUS
Merus
MRUS
+$34.1M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$101M
2
AMRN
Amarin Corp
AMRN
+$60.8M
3
XNCR icon
Xencor
XNCR
+$55.2M
4
ALXO icon
ALX Oncology
ALXO
+$46.6M
5
RCUS icon
Arcus Biosciences
RCUS
+$30.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.46%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XFOR icon
51
X4 Pharmaceuticals
XFOR
$372M
$9.4M 0.35%
36,386
+9,956
+38% +$2.62M
TNGX icon
52
Tango Therapeutics
TNGX
$4.4B
$8.9M 0.33%
800,000
– –
PNT
53
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$8.12M 0.3%
772,226
-182,770
-19% -$2.48M
VRDN icon
54
Viridian Therapeutics
VRDN
$2.11B
$7.75M 0.29%
463,504
+453,757
+4,655% +$8.5M
RNTX
55
Rein Therapeutics
RNTX
$63.3M
$7.53M 0.28%
+263,278
New +$9.02M
GLMD icon
56
Galmed Pharmaceuticals
GLMD
$4.96M
$6.17M 0.23%
9,998
– –
RACB
57
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$5.13M 0.19%
+500,000
New +$5.12M
FLACU
58
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$5.11M 0.19%
500,000
– –
EUCRU
59
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$5.03M 0.19%
500,000
– –
FVAM
60
DELISTED
5:01 Acquisition Corp
FVAM
$4.97M 0.19%
500,000
– –
PHXM
61
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$4.47M 0.17%
62,500
– –
FWP
62
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$4.43M 0.17%
647,299
– –
SNDX icon
63
Syndax Pharmaceuticals
SNDX
$1.67B
$3.66M 0.14%
163,524
-715,000
-81% -$16.2M
JYAC
64
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.95M 0.11%
300,000
– –
IVA
65
Inventiva
IVA
$1.04B
$1.57M 0.06%
+107,000
New +$1.64M
RZLT icon
66
Rezolute
RZLT
$449M
$1.35M 0.05%
190,815
+1
+0% +$12
SNCE
67
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$1.01M 0.04%
5,000
– –
ALXO icon
68
ALX Oncology
ALXO
$260M
– –
-540,837
Closed -$46.6M
CRIS icon
69
Curis
CRIS
$9.69M
– –
-1,567
Closed -$5.13M
CYTK icon
70
Cytokinetics
CYTK
$10.6B
– –
-4,878,035
Closed -$101M
PHAT icon
71
Phathom Pharmaceuticals
PHAT
$752M
– –
-150,787
Closed -$5.01M
RGLS
72
DELISTED
Regulus Therapeutics
RGLS
– –
-337,621
Closed -$4.56M
SWTX
73
DELISTED
SpringWorks Therapeutics
SWTX
– –
-50
Closed -$4K
XNCR icon
74
Xencor
XNCR
$1.51B
– –
-1,264,754
Closed -$55.2M
GMDA
75
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-1,343,667
Closed -$11.3M
1 2
3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2021 Portfolio in Review

As of Q1 2021, BVF Inc held 77 positions worth $2.67B, up 4.9% from $2.54B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

BVF Inc's Q1 2021 filing shows 9 new, 18 increased, 19 reduced and 10 closed positions. Its largest new stake was ImageneBio Inc: 133,305 shares worth $45.2M. The largest sale was Cytokinetics, an estimated $101M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • BVF Inc's largest Q1 2021 buy was ImageneBio Inc: 133,305 shares worth $45.2M.
  • BVF Inc added most to Five Prime Therapeutics, Inc. in Q1 2021, an estimated $132M increase.
  • BVF Inc's biggest Q1 2021 reduction was Amarin Corp, cutting an estimated $60.8M.
  • BVF Inc fully exited Cytokinetics in Q1 2021, selling an estimated $101M.
  • BVF Inc's ten largest holdings make up 52% of its $2.67B portfolio in Q1 2021.
  • BVF Inc opened 9 new positions and closed 10 in Q1 2021.
  • BVF Inc's portfolio value rose 4.9% quarter-over-quarter to $2.67B.

Based on BVF Inc's 13F filing for Q1 2021, filed 17 May 2021.